Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

It does not matter whether it is a tax dodge or not, we must look at it on the face of current legislation the UK have agreed. We live in a supposedly democracy, and no matter how politicians ply their trade and consequently put one another down to gain their own prestige and votes, and try to show they are concerned about UK research and jobs, it should still be democratic. We do not live in a dictatorship, nor are we a communist country, free trade should negotiable for all, no matter how big or small.

Pfizer are offering good money, and they are not going to say " we may increase", but will say "this is our final offer". This is how I would buy any business. I would "take it to the wire", and I would expect this of Americans. So perhaps we do not need to ask Pfizers motives, or listen to Politicians propaganda, but look at value for money ?

If the price is right - take the cash and run. I understand the Directors have said , that if the price was increased by 10% from £53.50, then they would recommend the offer.
AZ shares have been trading at about £28 for some time previously, and now we have a forecast of, if research is successful, then better times ahead and ? a doubling of the share price to over £55 ??? - I doubt it, and would not be prepared to wait about 4 /5 years to see if it is proven to be correct or not.
I think shareholders should take the good cash offered, and reinvest it elsewhere - it could be a gain for the UK economy, not a loss as protective politicians believe. Buy a Chinese bank or something instead of having AZ ?

It will be interesting to see what happens over the next few weeks. Remember also we have a Takeover code, and they could come back again after a suitable time lapse.

Let me know what your thought are - in this ( is it free country ) democracy.

PFIZER FINAL PROPOSAL TO ASTRAZENECA

STATEMENT FROM PFIZER INC.

FINAL PROPOSAL TO ASTRAZENECA




This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the "Code"). It does not represent a firm intention to make an offer under Rule 2.7 of the Code. Accordingly, there can be no certainty that any offer will ultimately be made.


In response to enquiries from market participants, Pfizer would like to confirm the following in respect of its announcement of 18 May 2014 which set out its final proposal to AstraZeneca (the "Final Proposal Announcement").

In the Final Proposal Announcement, Pfizer announced a possible offer comprising, for each AstraZeneca share, 1.747 shares in the combined entity and 2,476 pence in cash, representing an indicative value of £55.00. Pfizer stated that this proposal is final and cannot be increased except in limited circumstances specified in the Final Proposal Announcement. In addition, Pfizer stated that it will not make a hostile offer and will only announce a firm offer with the recommendation of the AstraZeneca board.

The effect of Pfizer's Final Proposal Announcement under the Takeover Code is that Pfizer will not be permitted to announce a firm offer unless such offer is on terms no higher than those set out in the Final Proposal Announcement (save as set out below) and such offer is recommended by AstraZeneca's board. Pfizer must, by 5.00 p.m. on 26 May 2014 or such later date as the Panel may agree at AstraZeneca's request, announce such a recommended firm offer or make a statement that it does not intend to make an offer for AstraZeneca. If Pfizer states that it does not intend to make an offer, Pfizer will be subject to the restrictions in Rule 2.8 and Note 2 on Rule 2.5 of the Code.


Pursuant to the Code, Pfizer will only be entitled to increase the final proposal in the following limited circumstances:

· If Pfizer's share price and/or the dollar/pound exchange rate changes such that the indicative value of Pfizer's final proposal would be less than £55.00 at the time of any firm offer announcement, then Pfizer has reserved the right to add further cash or Pfizer shares to its proposal in order to restore the indicative value of its offer to £55.00 (but no higher).

· Also, Pfizer has reserved the right to increase its proposal if, prior to the announcement of a firm offer by Pfizer, a third party announces a firm intention to make an offer for AstraZeneca pursuant to Rule 2.7 of the Code which, at the date Pfizer announces a firm offer for AstraZeneca, is valued at a price which is higher than the then indicative value of Pfizer's final proposal.

· If AstraZeneca ultimately decides to recommend Pfizer's final proposal and Pfizer announces a recommended offer on the terms set out in the Final Proposal Announcement, then Pfizer has reserved the right subsequently to increase its offer at any time. However, it is important to note that such right may be exercised only after Pfizer has obtained a recommendation from the AstraZeneca board of the terms set out in the Final Proposal Announcement and announced a recommended firm offer on this basis.

Pfizer has also made statements in the Final Proposal Announcement which reserve Pfizer's right to introduce other forms of consideration, vary the mix of consideration and reduce its proposal in certain circumstances.

A copy of this announcement will be available on Pfizer's website at www.pfizerupdate.com.

(Reuters) - Pfizer abandoned its attempt to buy AstraZeneca for nearly 70 billion pounds ($118 billion) on Monday as a deadline approached without a last-minute change of heart by the British drugmaker.

The decision ends a month-long public fight between two of the world's biggest pharmaceutical companies that sparked political concerns on both sides of Atlantic over jobs and corporate tax manoeuvres.

British rules now require an enforced cooling-off period. AstraZeneca could reach out to Pfizer after three months and Pfizer could take another run at its smaller British rival in six months time, whether it is invited back or not.

Astrazenica ceo bought £2m of AZN shares yday-if he is so confident then so am I and as a result jumped as a punt on the bandwagon

Down 5% due to the following:
Deutsche Bank "The US Treasury has announced a package of measures designed to stop US companies taking advantage of inversion deals, including "spin-versions". These appear more far-reaching than anticipated (although they are not retroactive for deals already completed). It is unclear whether the moves threaten completion of to-be-consummated deals, given that other benefits (cost savings, pipeline expansion, strategic elements) may still be sufficient to justify such deals proceeding and that the extent to which the Treasury changes impact the financial benefits cannot be quantified externally (we await the first formal response from one of the pending US acquirors). Regarding AstraZeneca, we note that Pfizer never quantified the extent to which tax benefits were important to its evaluation of the company and thus - with other strategic attractions (oncology pipeline, EM expansion etc) - it is unclear to us whether, or to what extent, the overnight news materially diminishes the chance of Pfizer renewing its interest post 26 November."

Green light in Europe for AZN ovarian cancer drug

Also: News

,Results and news

Feb 5:

Berenberg: Hold - TP: 4800p
Jefferies: Buy - TP: 5600p,
Liberum Capital: Buy - TP: 5800p
Shore Capital: Buy

Feb 6:
Panmure Gordon: Buy - TP: 5000p
Beaufort Securities: Hold - TP: N/A
Deutsche Bank: Hold - TP: 4800p

Questor/Telegraph says Hold/Solid long term investment

Feb 9: Citigroup: Buy - TP: 5400p

Questor share tip: AstraZeneca remains solid long term investment

Feb 10: Barclays: Underweight - TP: 4400p

Feb 13: Credit Suisse -Neutral - TP: 4670p

AZN Airways

Astra Zeneca's patent on asthma drug invalidated by US court

Astra considering appeal

Feb 20: Jefferies: Buy - TP: 5600p

Feb 24:

Kepler Cheuvreux: Reduce - TP: 3700p
Credit Suisse: Neutral - TP: 4670p

Feb 25:
Citigroup: Buy - TP: 5400p
JP Morgan: Neutral - TP: 4300p